These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21093451)

  • 1. Cardiac gene therapy with SERCA2a: from bench to bedside.
    Gwathmey JK; Yerevanian AI; Hajjar RJ
    J Mol Cell Cardiol; 2011 May; 50(5):803-12. PubMed ID: 21093451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcoplasmic reticulum and calcium cycling targeting by gene therapy.
    Hulot JS; Senyei G; Hajjar RJ
    Gene Ther; 2012 Jun; 19(6):596-9. PubMed ID: 22673498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of gene therapy as a treatment for heart failure.
    Hajjar RJ
    J Clin Invest; 2013 Jan; 123(1):53-61. PubMed ID: 23281410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases.
    Lipskaia L; Hadri L; Lopez JJ; Hajjar RJ; Bobe R
    Curr Vasc Pharmacol; 2013 Jul; 11(4):465-79. PubMed ID: 23905641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for heart failure: where do we stand?
    Naim C; Yerevanian A; Hajjar RJ
    Curr Cardiol Rep; 2013 Feb; 15(2):333. PubMed ID: 23307169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescuing the failing heart by targeted gene transfer.
    Kawase Y; Ladage D; Hajjar RJ
    J Am Coll Cardiol; 2011 Mar; 57(10):1169-80. PubMed ID: 21371634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for heart failure.
    Tilemann L; Ishikawa K; Weber T; Hajjar RJ
    Circ Res; 2012 Mar; 110(5):777-93. PubMed ID: 22383712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for heart failure.
    Greenberg B
    J Cardiol; 2015 Sep; 66(3):195-200. PubMed ID: 25818479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).
    Greenberg B; Yaroshinsky A; Zsebo KM; Butler J; Felker GM; Voors AA; Rudy JJ; Wagner K; Hajjar RJ
    JACC Heart Fail; 2014 Feb; 2(1):84-92. PubMed ID: 24622121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting sarcoplasmic reticulum calcium ATPase by gene therapy.
    Gwathmey JK; Yerevanian A; Hajjar RJ
    Hum Gene Ther; 2013 Nov; 24(11):937-47. PubMed ID: 24164241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SERCA2a gene therapy for heart failure: ready for primetime?
    Periasamy M; Kalyanasundaram A
    Mol Ther; 2008 Jun; 16(6):1002-4. PubMed ID: 18500238
    [No Abstract]   [Full Text] [Related]  

  • 12. Gene therapy in heart failure. SERCA2a as a therapeutic target.
    Hayward C; Patel H; Lyon A
    Circ J; 2014; 78(11):2577-87. PubMed ID: 25327883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramyocardial injection of SERCA2a-expressing lentivirus improves myocardial function in doxorubicin-induced heart failure.
    Mattila M; Koskenvuo J; Söderström M; Eerola K; Savontaus M
    J Gene Med; 2016 Jul; 18(7):124-33. PubMed ID: 27203155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.
    Lipskaia L; Chemaly ER; Hadri L; Lompre AM; Hajjar RJ
    Expert Opin Biol Ther; 2010 Jan; 10(1):29-41. PubMed ID: 20078230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarcoendoplasmic reticulum calcium transport ATPase 2a: a potential gene therapy target in heart failure.
    Papolos A; Frishman WH
    Cardiol Rev; 2013; 21(3):151-4. PubMed ID: 23568057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in gene therapy for heart failure.
    Fish KM; Ishikawa K
    Discov Med; 2015 Apr; 19(105):285-91. PubMed ID: 25977191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.
    Zsebo K; Yaroshinsky A; Rudy JJ; Wagner K; Greenberg B; Jessup M; Hajjar RJ
    Circ Res; 2014 Jan; 114(1):101-8. PubMed ID: 24065463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides.
    Zhai Y; Luo Y; Wu P; Li D
    J Med Genet; 2018 May; 55(5):287-296. PubMed ID: 29478009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved cardiac function after sarcoplasmic reticulum Ca(2+)-ATPase gene transfer in a heart failure model induced by chronic myocardial ischaemia.
    Xin W; Li X; Lu X; Niu K; Cai J
    Acta Cardiol; 2011 Feb; 66(1):57-64. PubMed ID: 21446381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correcting Calcium Dysregulation in Chronic Heart Failure Using SERCA2a Gene Therapy.
    Samuel TJ; Rosenberry RP; Lee S; Pan Z
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29621141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.